Table 1.
The main immune checkpoint inhibitors approved for treatment of advanced hepatocellular carcinoma
|
Drug
|
Mechanism of action
|
Efficacy
|
Safety
|
Approval
|
| First-line | ||||
| Atezolizumab (1200 mg, IV) plus bevacizumab (15 mg/kg, IV) every 3 wk | ICI, anti-PD-L1 antibody (atezolizumab) plus antiangiogenic, anti-VEGF-A antibody (bevacizumab) | Improved OS, PFS, ORR vs sorafenib (IMbrave-150 phase III trial[93]) | irAEs1, hypertension, fatigue, proteinuria, pruritus, gastrointestinal bleeding | Approved by FDA and EMA for patients with advanced HCC |
| Tremelimumab (300 mg, IV) plus durvalumab (1500 mg, IV) once, followed by durvalumab (1500 mg, IV) every 4 wk | ICI, anti-CTLA-4 antibody (tremelimumab) plus ICI, anti-PD-L1 antibody (durvalumab) | Improved OS vs sorafenib and favorable benefit-risk ratio (HIMALAYA phase III trial[89]) | Pruritus, irAEs1 | Under evaluation for approval. Granted orphan drug designation by FDA for HCC treatment (2020) |
| Sintilimab (200 mg, IV) plus IBI305 (bevacizumb biosimilar; 15 mg/kg, IV) every 3 wk | ICI, anti-PD-1 antibody (sintilimab) plus antiangiogenic, anti-VEGF-A antibody (IBI305) | Better OS and PFS in HBV-related advanced HCC vs sorafenib (ORIENT-32 phase II/III trial[113]) | Proteinuria, irAEs1, thrombocytopenia, leukopenia, hypertension, fatigue | Approved by NMPA in China for patients with advanced HCC (2021) |
| Second-line | ||||
| pembrolizumab (200 mg, IV) every 3 wk plus best supportive care | ICI, anti-PD-1 monoclonal antibody | Better OS, PFS and ORR in patients post-sorafenib vs placebo (KEYNOTE-394 phase III trial[114] and KEYNOTE-224 phase II trial[115]) | irAEs1, fatigue, pruritus, anorexia | Approved by FDA for advanced HCC post-sorafenib (2018) |
| Nivolumab (1 mg/kg, IV) plus ipilimumab (3 mg/kg, IV) every 3 wk for 4 cycles, followed by nivolumab (240 mg, IV) every 2 wk | ICI, anti-PD-1 monoclonal antibody (nivolumab) plus ICI, anti-CTLA-4 antibody (ipilimumab) | Promising OS and durable response post-sorafenib (cohort 4 of CheckMate-040 phase I/II trial[90]). CheckMate 9DW phase III trial ongoing[116] | Pruritus, irAEs1 | Approval by FDA for advanced HCC post-sorafenib (2020) |
1
Immune-related adverse events include hepatitis, colitis, pneumonia, endocrinopathy, skin rash, neurological disorders.
IV: Intravenous administration; ICI: Immune checkpoint inhibitor; VEGF-A: Vascular endothelial growth factor-A; OS: Overall survival; PFS: Progression free survival; ORR: Objective response rate; irAEs: Immune-related adverse events; FDA: Food and Drug Administration; EMA: European Medicines Agency; HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; NMPA: National Medical Products Administration.